AIMT

PALFORZIA®

Peanut Allergy | POSEIDON

Stage (next event)

Expected Date

Phase 3 (Data)

TBD

Catalyst Info & Data Links

We will not be following this anymore because AIMT was bought by Nestle 

Nestlé Completes Acquisition of Aimmune Therapeutics


TITLE: PALFORZIA® in Peanut Allergy - Phase 3 Data

  • ClinicalTrial.gov (NCT03736447): Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)


WHAT IS THE CATALYST EVENT?


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • H2 2021


PRIOR DATA

PRESS RELEASES


Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

Amp Core Q2 '19 Report

FDA Accepts AIMT's Peanut Allergy Treatment BLA For Review

Amp Mid-Q1 '19 Update

AIMT Mid-Q1 '19 Update

Update on Aimmune Therapeutics Versus DBV Technologies Peanut Allergy-Related Candidate Treatments

AIMT and DBVT: Two different approaches to peanut allergy that are likely to eventually become comme

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon